ReviewJACC. Heart failure2025
Contemporary Antibody-Mediated Rejection in Heart Transplantation: JACC: Heart Failure Position Statement.
Review in JACC. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Graft rejection across solid organ transplants: mechanisms, monitoring, and immunosuppressive therapeutics.Frontiers in surgery · 2026Pooled it
- Precision Immunosuppression in Heart Transplantation: Biomarker-Guided Therapy Comes of Age.Current heart failure reports · 2026Review
- Beyond Tacrolimus: Toward Personalized Immunosuppression in Heart Transplantation.Journal of cardiac failure · 2026Review
- Prognostic value of early cardiac magnetic resonance first-pass perfusion assessment of microcirculatory dysfunction for acute rejection after heart transplantation.Cardiovascular diagnosis and therapy · 2026Article
- The gut microbiome and allograft outcomes: implications for heart transplantation.The Journal of clinical investigation · 2026Review
- Serum CA125 for Detection of Antibody-Mediated Rejection in Heart Transplantation Recipients.International journal of molecular sciences · 2026Article
- A rare case of giant cardiac malignant tumor with positive panel reactive antibody.Journal of cardiothoracic surgery · 2026Article
- Role of Cardiovascular Magnetic Resonance in Post-Heart Transplant Surveillance: Integrating Evidence with Prospective Cohort Data.Journal of personalized medicine · 2026Article
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.Frontiers in immunology · 2026Review
- A review of immunosuppressive therapy in the context of uterine VCA and pregnancy.Frontiers in transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Heart transplantation remains the definitive therapy for patients with advanced heart failure. Acute and chronic rejection affect both short- and long-term outcomes. Antibody-mediated rejection (AMR) remains a leading cause of graft failure and mortality. The reported incidence of AMR varies widely, on the basis of patient characteristics, variability in the interpretation of endomyocardial biopsy, and differences in clinical thresholds at which to treat AMR. There has been increased recognition of the role of human leukocyte antigen donor-specific antibodies and molecular diagnostics, such as donor-derived cell-free DNA or intragraft gene expression, in supporting the diagnosis of AMR beyond histopathology alone. Furthermore, therapeutic management of patients with AMR previously focused on quelling inflammation, removing or neutralizing pathological antibodies, and blocking antibody-producing cells. Novel therapies now also target complement-mediated injury, costimulatory blockade, and specific cytokine-mediated inflammatory pathways. This position statement highlights contemporary diagnostic and therapeutic approaches for AMR after heart transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.